Point72 Asset Management Discloses 4.4% Stake in Design Therapeutics, Inc. (DSGN)

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc. and Steven A. Cohen, filed a Schedule 13G/A on May 15, 2026, disclosing a new beneficial ownership position in Design Therapeutics, Inc. (DSGN). As of the event date on March 31, 2026, the reporting persons collectively hold 2,722,754 shares of common stock, representing a 4.4% stake in the company. This represents an increase from a previous 0.0% holding reported. The shares are held by an investment fund managed by Point72 Asset Management. Point72 Capital Advisors, Inc. serves as the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. Sub-advisors including Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited, and Point72 Asia (Singapore) Pte. Ltd. also act with respect to portions of the reported shares. The filing indicates that the securities were acquired for investment purposes and not with the intent to influence or change the control of the issuer. Since the ownership level is now below the 5% threshold, the filers have checked the box indicating they have ceased to be beneficial owners of more than five percent of the class of securities.